Unlike the discovery of HIF-2 inhibitors, which has been notably successful with the identification of PT-2385 for the treatment of renal cancers [41], there are a lack of direct HIF-1 inhibitors, with two of the better inhibitors, acriflavine and PX-478, showing non-specificity and indirect mechanisms of action [46,47,48]. The gene discussed is HIF1A; the disease is renal carcinoma.